Soluble VCAM-1 serum levels were reported to positively correlate in MS patients with clinical disease activity and an inflammatory BBB breakdown as indicated by Gadolinium-enhancing MRI lesions [38], [39]. Here, VCAM1 is linked to myeloid sarcoma.